CareDx, Inc.
CDNA Healthcare Diagnostics & Research
CareDx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $379.8 million, up 13.8% from fiscal 2024.
- Revenue
- +39.3%
- EPS
- +1,133.3%
- Free cash flow
- −68.6%
Quarter to September 2026, against a year earlier
Follow CDNA
Alert me
CareDx, Inc. (CDNA) P/S ratio
As of 5 November 2026, CareDx, Inc. (CDNA) trades at a P/S ratio of 8.1×. Over the past ten years it has ranged from 0.4× (April 2017) to 23.1× (January 2021); the current reading is higher than 74% of that period. That is above the Diagnostics & Research industry median of 4.2× and above the Healthcare sector median of 3.5×.
P/S ratio, daily
Embed this chart
Annual newest first
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 2.6× | (21.91%) |
| FY2024 | 3.4× | 47.82% |
| FY2023 | 2.3× | 24.50% |
| FY2022 | 1.8× | (77.05%) |
| FY2021 | 8.0× | (54.25%) |
| FY2020 | 17.5× | 144.88% |
| FY2019 | 7.2× | (38.85%) |
| FY2018 | 11.7× | 243.74% |
| FY2017 | 3.4× | 264.54% |
| FY2016 | 0.9× | (65.38%) |
Quarterly newest first
| Period | P/S ratio | Change |
|---|---|---|
| Sep 2026 | 6.8× | 112.69% |
| Jun 2026 | 3.2× | 48.87% |
| Mar 2026 | 2.2× | (18.62%) |
| Dec 2025 | 2.6× | 23.95% |
| 43 more quarters | Free account |
Against its own ten years
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| RDNT RadNet, Inc. compare | 2.7× |
| NEO NeoGenomics, Inc. compare | 2.7× |
| VCYT Veracyte, Inc. compare | 3.3× |
| SHC Sotera Health Company compare | 3.7× |
| WGS GeneDx Holdings Corp. compare | 4.2× |
| CDNA CareDx, Inc. | 8.1× |
| BLLN BillionToOne, Inc. compare | 12.1× |
| ADPT Adaptive Biotechnologies Corporation compare | 14.5× |
| GRAL GRAIL, Inc. compare | 34.9× |
| Diagnostics & Research industry median | 4.2× |
| Healthcare sector median | 3.5× |
| Market median | 1.9× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on CDNA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement